MAPT and Alzheimer disease: Until a recent report of lecanemab3, clinical trials of anti-amyloid monoclonal antibodies4-6, secretase inhibitors7,8, and anti-tau monoclonal antibodies9,10 have had limited success in symptomatic AD patients.